Duke University is a private research university located in Durham, North Carolina, United States. Founded by Methodists and Quakers in the present-day town of Trinity in 1838, the school moved to Durham in 1892. In 1924, tobacco and electric power industrialist James B. Duke established The Duke Endowment, at which time the institution changed its name to honor his deceased father, Washington Duke.The university's campus spans over 8,600 acres on three contiguous campuses in Durham as well as a marine lab in Beaufort. Duke's main campus—designed largely by African American architect Julian Abele—incorporates Gothic architecture with the 210-foot Duke Chapel at the campus' center and highest point of elevation. The first-year-populated East Campus contains Georgian-style architecture, while the main Gothic-style West Campus 1.5 miles away is adjacent to the Medical Center.Duke's research expenditures in the 2012 fiscal year were $1.01 billion, the seventh largest in the nation. Competing in the Atlantic Coast Conference, Duke's athletic teams, known as the Blue Devils, have captured 15 team national championships, including four by its high profile men's basketball team. Duke was ranked among the world's best universities by both THE and QS, while tying for 8th in the 2015 U.S. News & World Report "Best National Universities Rankings." In 2014, Thomson Reuters named 32 Duke professors to its list of Highly Cited Researchers. The only schools with more primary affiliations were Harvard, Stanford, and UC Berkeley. Wikipedia.
Los Alamos National Security LLC, Beth Israel Deaconess Medical Center, Duke University and University of Alabama at Birmingham | Date: 2017-06-14
The present invention relates, in general, to an immunogenic composition (e.g., a vaccine) and, in particular, to a polyvalent immunogenic composition, such as a polyvalent HIV vaccine, and to methods of using same. The invention further relates to methods that use a genetic algorithm to create sets of polyvalent antigens suitable for use, for example, in vaccination strategies.
Immunolight Llc and Duke University | Date: 2017-02-16
A system for treating a diseased site in a human or animal body. The system includes a pharmaceutical carrier including one or more phosphors which are capable of emitting light into the diseased site upon interaction, a photoactivatable drug for intercalating into DNA of cells at the diseased site, one or more devices which infuse the diseased sited with the photoactivatable drug and the pharmaceutical carrier, an x-ray or high energy electron source, and a processor programmed to control a dose of x-rays or electrons to the diseased site for production of light inside the tumor to activate the photoactivatable drug.
Duke University | Date: 2017-02-21
The present invention relates, in general, to a method of treating patients undergoing enzyme replacement therapy (ERT) or other therapy involving the administration of a proteinaceous therapeutic agent as well gene replacement therapy with non-viral or viral vectors, or other therapeutic modality or modalities, used alone or in combination, which involve the administration of exogenous substances for potential therapeutic benefit, including, but not limited to DNA vaccines, siRNA, splice-site switching oligomers (SSOs) as well as RNA-based nanoparticles (RNPs) and nanovaccines. The invention further relates to compounds and compositions suitable for use in such methods.
Duke University | Date: 2017-03-02
Methods and systems for assessing pulmonary gas exchange and/or alveolar-capillary barrier status include obtaining at least one MRI image and/or image data of ^(129)Xe dissolved in the red blood cells (RBC) in the gas exchange regions of the lungs of a patient. The image is sufficiently sensitive to allow a clinician or image recognition program to assess at least one of pulmonary gas exchange, barrier thickness or barrier function based on the ^(129)Xe MRI RBC image.
Duke University | Date: 2017-03-06
An arteriovenous dialysis access graft configured to be implanted in a subject includes: at least one flexible conduit having first and second end portions, wherein the first end portion is configured to connect to an artery of the subject and the second end portion is configured to connect to a vein of the subject such that blood flows through the at least one conduit; and at least one cannulation chamber positioned between the first end portion and the second end portion of the at least one conduit. The chamber includes: an elongated housing having an inlet and an outlet, a posterior wall, a pair of sidewalls, and an open anterior portion defining a cannulation port; and a self-sealing material extending across the cannulation port. The posterior wall and the sidewalls of the housing are formed of a substantially rigid material.
Immunolight Llc. and Duke University | Date: 2017-02-27
A method and a system for producing a change in a medium disposed in an artificial container. The method places in a vicinity of the medium at least one of a plasmonics agent and an energy modulation agent. The method applies an initiation energy through the artificial container to the medium. The initiation energy interacts with the plasmonics agent or the energy modulation agent to directly or indirectly produce the change in the medium. The system includes an initiation energy source configured to apply an initiation energy to the medium to activate the plasmonics agent or the energy modulation agent.
Duke University | Date: 2017-06-14
Provided herein are methods for identifying and treating subjects having conditions involving reduced HSF1 activity (e.g., diminished HSF1 activity, diminished HSF1 protein levels, increased HSF1 Ser303 phosphorylation, increased HSF1 Ser307 phosphorylation) or conditions that benefit from increasing HSF1 abundance or activity beyond physiological levels.
Duke University | Date: 2017-05-31
The present invention relates, in general, to obesity, and, in particular, to a method of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight-loss promoting anticonvulsant either alone or in combination with bupropion or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.
Duke University | Date: 2017-01-18
A polymer-free synthesis method is provided for preparation of monodisperse nanostars. The nanostars can be used for treating and imaging cells in in vivo or ex vivo. The modes of treatment include use of a nanostar modified with a photo-activatable drug, which drug is activated by the photo-response of the nanostar to electromagnetic stimulation; use of a nanostar modified with a thermally-activatable drug, which drug is activated by a thermal response of the nanostar to electromagnetic stimulation; and the thermal response of the nanostar itself to electromagnetic stimulation, which can directly or indirectly cause the death of an undesirable cell.
Duke University | Date: 2017-05-17
Methods of reducing the likelihood of a cancer or precancer developing resistance to a cancer therapeutic or prevention agent are provided herein. The methods include administering a vaccine comprising a polynucleotide encoding a poiypeptide whose expression or activation is correlated with development of resistance of the cancer or precancer to the cancer therapeutic or prevention agent to a subject. The vaccine may include a polynucleotide encoding a HER2 poiypeptide or a truncation, deletion or subsiitiition mutant thereof. Methods of using the vaccine including the polynucleotide encoding the HER2 polypeptide to treat a cancer or precancer are also provided. The vaccines may be administered with a cancer therapeutic or prevention agent or a checkpoint inhibitor immunomodulatory agent.